Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity.

Détails

ID Serval
serval:BIB_799F312B64CC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity.
Périodique
European Heart Journal
Auteur(s)
Quercioli A., Pataky Z., Vincenti G., Makoundou V., Di Marzo V., Montecucco F., Carballo S., Thomas A., Staub C., Steffens S., Seimbille Y., Golay A., Ratib O., Harsch E., Mach F., Schindler T.H.
ISSN
1522-9645 (Electronic)
ISSN-L
0195-668X
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
32
Numéro
11
Pages
1369-1378
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
AIMS: Aim of this study was to evaluate a possible association between endocannabinoid (EC) plasma levels, such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and coronary circulatory function in obesity.
METHODS AND RESULTS: Myocardial blood flow (MBF) responses to cold pressor test (CPT) and during pharmacological vasodilation with dipyridamole were measured with (13)N-ammonia PET/CT. Study participants (n = 77) were divided into three groups based on their body mass index (BMI, kg/m(2)): control group 20 ≤ BMI <25 (n = 21); overweight group, 25 ≤ BMI <30 (n = 26); and obese group, BMI ≥ 30 (n = 30). Anandamide plasma levels, but not 2-AG plasma levels, were significantly elevated in obesity as compared with controls, respectively [0.68 (0.53, 0.78) vs. 0.56 (0.47, 0.66) ng/mL, P = 0.020, and 2.2 (1.21, 4.59) vs. 2.0 (0.80, 5.90) ng/mL, P = 0.806)]. The endothelium-related change in MBF during CPT from rest (ΔMBF) progressively declined in overweight and obese when compared with control group [0.21 (0.10, 0.27) and 0.09 (-0.01, 0.15) vs. 0.26 (0.23, 0.39) mL/g/min; P = 0.010 and P = 0.0001, respectively). Compared with controls, hyperaemic MBFs were significantly lower in overweight and obese individuals [2.39 (1.97, 2.62) vs. 1.98 (1.69, 2.26) and 2.10 (1.76, 2.36); P = 0.007 and P = 0.042, respectively)]. In obese individuals, AEA and 2-AG plasma levels were inversely correlated with ΔMBF to CPT (r = -0.37, P = 0.046 and r = -0.48, P = 0.008) and hyperaemic MBFs (r = -0.38, P = 0.052 and r = -0.45, P = 0.017), respectively.
CONCLUSIONS: Increased EC plasma levels of AEA and 2-AG are associated with coronary circulatory dysfunction in obese individuals. This observation might suggest increases in EC plasma levels as a novel endogenous cardiovascular risk factor in obesity, but needing further investigations.
Mots-clé
Aged, Arachidonic Acids/metabolism, Body Mass Index, Cannabinoid Receptor Modulators/blood, Case-Control Studies, Coronary Circulation/physiology, Coronary Disease/blood, Coronary Disease/etiology, Endocannabinoids, Female, Glycerides/metabolism, Hemodynamics/physiology, Humans, Male, Middle Aged, Obesity/blood, Obesity/complications, Polyunsaturated Alkamides/metabolism, Positron-Emission Tomography
Pubmed
Web of science
Open Access
Oui
Création de la notice
09/02/2015 14:42
Dernière modification de la notice
08/05/2019 20:43
Données d'usage